CIA
STML

Capital Impact Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Capital Impact Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,116
Closed -$173K – 321
2014
Q4 		$173K Hold
10,116
– – 0.08% 141
2014
Q3 		$126 Hold
10,116
– – ﹤0.01% 191
2014
Q2 		$148K Buy
+10,116
New +$155K 0.11% 202

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Impact Advisors's STML Position: Q1 2015 in Review

Capital Impact Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q1 2015, closing a stake of 10,116 shares — an estimated $173K sold.

Capital Impact Advisors first reported a position in STML in Q2 2014 and held it in 3 quarters. The position peaked at $173K in Q4 2014. 69 funds tracked by Wall St. Rank hold STML as of Q1 2015.

  • Capital Impact Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 10,116 Stemline Therapeutics, Inc. shares in Q1 2015, an estimated $173K.
  • Capital Impact Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
  • Capital Impact Advisors's Stemline Therapeutics, Inc. position peaked at $173K in Q4 2014.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2015.

Based on Capital Impact Advisors's 13F filing for Q1 2015, filed 29 May 2015.